Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.

We report the effect of continuous treatment with alendronate for 6 yr vs. placebo in the Early Postmenopausal Intervention Cohort study. A total of 1609 healthy, early postmenopausal women were recruited; we describe results for the 585 women who received continuous placebo or alendronate (2.5 or 5 mg) daily for 6 yr. Bone mineral density (BMD) was evaluated at the lumbar spine, hip, forearm, and total body at baseline and annually thereafter. Bone turnover markers were measured every 6 months from baseline to yr 2 and annually thereafter. Adverse experiences, including upper gastrointestinal events and fractures, were recorded throughout the study. Women receiving placebo experienced progressive decreases in BMD at all skeletal sites. Patients receiving alendronate experienced significant gains in spine and hip BMD that were maintained through yr 6. Significantly greater, dose-related decreases in bone turnover markers in the alendronate groups vs. placebo occurred within the first year and were sustained through yr 6. Women receiving alendronate had adverse experience incidences similar to those receiving placebo. Fractures occurred in 11.5, 10.3, and 8.9% of women taking placebo, 2.5 mg alendronate, or 5 mg alendronate daily, respectively. Therapy with alendronate is an effective and promising strategy for the prevention of postmenopausal osteoporosis.

[1]  S. Epstein,et al.  DIFFERENCES IN SERUM BONE GLA PROTEIN WITH AGE AND SEX , 1984, The Lancet.

[2]  C. Christiansen,et al.  Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  G. B. Lopes,et al.  Effects of estrogen plus progestin on health-related quality of life. , 2004, The New England journal of medicine.

[4]  Menopausal hormone replacement therapy and risk of ovarian cancer , 2002, JAMA.

[5]  C. Christiansen,et al.  Changes in bone density and turnover after alendronate or estrogen withdrawal , 2004, Menopause.

[6]  O Johnell,et al.  Bone loss in relation to menopause: a prospective study during 16 years. , 2001, Bone.

[7]  C. Coupland,et al.  Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. , 1999, Annals of internal medicine.

[8]  C. Christiansen,et al.  Changes in Bone Mineral Density with Age in Men and Women: A Longitudinal Study , 2002, Osteoporosis International.

[9]  L. Davis.  Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. , 1998, Journal of nurse-midwifery.

[10]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[11]  P. Delmas,et al.  Immunoassay of pyridinoline crosslink excretion in normal adults and in paget's disease , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[14]  W. O'Fallon,et al.  Relationship of Bone Turnover to Bone Density and Fractures , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  S. Ross.  Meta-analysis of prevention of nonvertebral fractures by alendronate. , 1997, JAMA.

[16]  S. Cummings,et al.  Design of the Fracture Intervention Trial , 2005, Osteoporosis International.

[17]  P. Delmas,et al.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  M. Gibaldi.  Prevention and Treatment of Osteoporosis: Does the Future Belong to Hormone Replacement Therapy? , 1997, Journal of clinical pharmacology.

[19]  S. Cummings,et al.  Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). , 2001, The American journal of medicine.

[20]  K. Mann,et al.  Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. , 1983, The Journal of clinical investigation.

[21]  Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis , 1992, British journal of obstetrics and gynaecology.

[22]  Are women using postmenopausal estrogens? A community survey. , 1991, American journal of public health.

[23]  R Don Gambrell,et al.  Women's Health Initiative , 2001 .

[24]  P. Delmas,et al.  Decreased bone turnover in oral contraceptive users. , 1995, Bone.

[25]  D R Shapiro,et al.  Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.

[26]  M. Hochberg,et al.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  J. Wark,et al.  The prevention and treatment of osteoporosis. , 1993, The New England journal of medicine.

[28]  R. Recker,et al.  Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .

[29]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[30]  P. Geusens,et al.  Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. , 1996, Bone.

[31]  J. Rodriguez-Portales,et al.  Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[32]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[33]  J. Eisman,et al.  Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial , 1998, Annals of Internal Medicine.

[34]  O Johnell,et al.  The socioeconomic burden of fractures: today and in the 21st century. , 1997, The American journal of medicine.

[35]  T. Schnitzer.  Update on alendronate for osteoporosis: once-weekly dosing , 2001, Expert opinion on pharmacotherapy.

[36]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[37]  P. Sambrook,et al.  Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  C. Christiansen,et al.  Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent. , 2002, Bone.

[39]  P. Delmas,et al.  Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[40]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[41]  D. Bauer,et al.  Physical Activity and Osteoporotic Fracture Risk in Older Women , 1998, Annals of Internal Medicine.